Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F17%3A00066117" target="_blank" >RIV/65269705:_____/17:00066117 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/17:10363636 RIV/00179906:_____/17:10363636

Result on the web

<a href="http://www.tandfonline.com/doi/full/10.1080/10428194.2016.1195497" target="_blank" >http://www.tandfonline.com/doi/full/10.1080/10428194.2016.1195497</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10428194.2016.1195497" target="_blank" >10.1080/10428194.2016.1195497</a>

Result language

angličtina

Original language name

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

Original language description

Relationships between patient characteristics, ofatumumab pharmacokinetics, and treatment outcomes were investigated in this phase 2 trial of ofatumumab plus fludarabine and cyclophospha-mide (FC) in untreated chronic lymphocytic leukemia. Patients were randomized 1:1 to receive 500 or 1000mg ofatumumab (Cycle 1; 300mg) plus FC every 4 weeks for six cycles. Median C-max and C-trough values were similar at Cycle 1 regardless of the ultimate clinical outcome. At later doses, these values were higher for patients with complete response (CR) than for other patients. Higher C-max and C-trough values at Cycles 3 and 6 were significantly associated with an increased likelihood of CR, whereas ofatumumab pharmacokinetics were not associated with an objective response (OR) on the basis of univariate analyses. Multivariate analyses indicated that baseline patient/disease factors were predominantly associated with CR (17p status) or OR (bulky lymph-adenopathy, gender, and serum thymidine kinase), rather than ofatumumab pharmacokinetics.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

—

Volume of the periodical

58

Issue of the periodical within the volume

2

Country of publishing house

US - UNITED STATES

Number of pages

9

Pages from-to

348-356

UT code for WoS article

000388601000013

EID of the result in the Scopus database

—